The North America Bioprocess Technology Market was valued at USD 12,410 Million in 2025 and is expected to reach USD 35,240 Million by 2035, growing at a CAGR of 10.2% from 2024 to 2035. This market encompasses a broad set of tools, equipment, and techniques used to optimize biological processes for the production of biopharmaceuticals, vaccines, biosimilars, and industrial enzymes across North America.
The economic impact of tariffs on "North America Bioprocess Technology Market".
Market Growth Drivers
Rising Demand for Biologics: The increasing adoption of biologics and biosimilars for treating chronic diseases such as cancer, rheumatoid arthritis, and diabetes is fueling demand for advanced bioprocess technologies. Leading manufacturers such as Thermo Fisher Scientific are investing in newer bioprocessing equipment and single-use systems to meet the diversified needs of the biopharmaceutical industry and accelerate time-to-market.
Technological Advancements and Automation: Companies like GE Healthcare and Merck KGaA are integrating advanced automation, digital sensors, and AI-driven process analytics into bioprocessing platforms. These innovations lead to improved yield, scalability, product quality, and process efficiency, driving market growth and reduced operational costs.
Market Trends
Expansion of Single-Use Technologies: The market is witnessing a significant shift towards single-use bioprocessing technologies, such as disposable bioreactors, filters, and tubing assemblies. Companies like Sartorius Stedim Biotech AG are launching new, scalable, single-use systems to reduce contamination risks, lower capital costs, and enable flexible multi-product manufacturing facilities.
Increased Adoption of Continuous Bioprocessing: Traditional batch processing is increasingly being replaced by continuous manufacturing models due to higher productivity and consistent product quality. Leading industry players, including Cytiva (Danaher Corporation), are developing integrated continuous bioprocess solutions that enable real-time monitoring and control, reducing time-to-market for new therapies.
Market Opportunities
Expanding Cell and Gene Therapy Manufacturing: The rapid growth of cell and gene therapy pipelines in North America represents significant opportunities for bioprocess technology providers, as companies like Lonza and Thermo Fisher Scientific invest in advanced solutions and infrastructure tailored to complex therapy development.
Growing Investment in Biomanufacturing Infrastructure: Increased funding and public-private collaborations are accelerating the establishment of new biomanufacturing facilities, offering lucrative opportunities for vendors of bioprocessing equipment and software to support diverse therapeutic modalities.
North America Bioprocess Technology Market Revenue (USD Million), 2020-2035
The chart depicts the steady growth trajectory of the North America Bioprocess Technology Market from 2020 to 2035. Starting at approximately USD 6,800 Million in 2020, the market demonstrates robust expansion year-on-year, driven by the rising adoption of biopharmaceuticals and technological advances in process optimization. By 2025, the revenue reaches USD 12,410 Million, and significant growth is sustained post-2025 due to increased demand for biologics, investments in innovative bioprocessing infrastructure, and new therapeutics commercialization. The market surpasses USD 20,000 Million by 2031 and is forecasted to reach USD 35,240 Million by 2035, reflecting a CAGR of 10.2%.
North America Bioprocess Technology Market by Region Share (%), 2025
This pie chart illustrates regional market shares for the North America Bioprocess Technology sector in 2025. The United States leads with a dominant share of 78%, owing to its established biopharmaceutical industry, research infrastructure, and significant government support. Canada holds 15% of the market, driven by expanding biomanufacturing initiatives and investments in innovation. Mexico follows with 5%, benefiting from lower manufacturing costs. Other regions, including Puerto Rico and rest of North America, collectively account for 2%. The dominance of the U.S. highlights its critical role in regional growth and innovation.
Recent Developments
June 2024: Cytiva (Danaher Corporation) announced the release of a next-generation continuous bioprocessing platform, designed to integrate real-time monitoring, automation, and digital twin technology for enhanced cell culture control. The new platform is already being adopted by several leading biopharmaceutical companies in the United States to accelerate biologics and vaccine development.
May 2024: Thermo Fisher Scientific entered into a strategic partnership with Bluebird Bio for the development of modular, closed-system bioprocessing solutions. The aim is to support scalable gene therapy manufacturing processes to meet increasing pipeline demands for personalized therapies.
April 2024: Lonza opened a new state-of-the-art cell and gene therapy manufacturing facility in Houston, Texas, enhancing the regional supply chain network and boosting capacity for commercial-scale viral vector and cell therapy production. The facility features advanced quality control labs and automated bioprocessing suites.
Press Releases